Multiple tumor-associated antigens (SV-BR-1-GM) (TAA (SV-BR-1-GM))

SV-BR-1-GM (Bria-IMT) is a genetically modified whole-cell breast cancer vaccine that serves as a source of multiple tumor-associated antigens (TAAs) to stimulate the immune system [1]. The cell line is engineered to secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), which acts as a potent adjuvant by recruiting and activating antigen-presenting cells (APCs), such as dendritic cells, to the site of administration [2]. These APCs internalize the diverse TAAs from the SV-BR-1-GM cells, process them, and present them to the patient's T cells, thereby initiating a systemic anti-tumor immune response [1, 3]. This approach is designed to bypass the immune evasion mechanisms of tumors by providing both the target antigens and the necessary co-stimulatory signals for T cell activation [2]. Clinical efficacy of the SV-BR-1-GM platform has been closely linked to the degree of Human Leukocyte Antigen (HLA) matching between the vaccine cell line and the patient, which is thought to facilitate more effective antigen presentation [3, 4]. By targeting a broad array of antigens rather than a single protein, the therapy aims to reduce the likelihood of tumor escape through antigen loss [1]. References: [1] BriaCell Therapeutics, "Bria-IMT™ (SV-BR-1-GM)", briacell.com. [2] Williams et al. (2023), "Targeted Immunotherapy of Metastatic Breast Cancer with SV-BR-1-GM", Cancer Gene Therapy. [3] ClinicalTrials.gov, NCT03328091. [4] Wiseman & Kharazi (2006), "Objective clinical regression of metastatic breast cancer with a combination of SV-BR-1-GM and GM-CSF", Breast Journal.

Other names

Bria-IMT targetsSV-BR-1-GM antigensBreast cancer tumor-associated antigensSV-BR-1-GM/GM-CSF pathway

The SV-BR-1-GM cell line expresses multiple tumor-associated antigens and secretes GM-CSF to recruit and activate antigen-presenting cells (APCs). These APCs process the antigens and present them to T cells, inducing a systemic anti-tumor immune response.